# RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

> **NCT03445650** · PHASE3 · COMPLETED · sponsor: **Aldeyra Therapeutics, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Sjogren-Larsson Syndrome

## Interventions

- **DRUG:** ADX-102 1% Topical Dermal Cream (reproxalap)
- **DRUG:** Vehicle of ADX-102 Topical Dermal Cream

## Key facts

- **NCT ID:** NCT03445650
- **Lead sponsor:** Aldeyra Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-18
- **Primary completion:** 2020-01-18
- **Final completion:** 2020-01-18
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03445650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03445650, "RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03445650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*